BioPharmSignal logoBioPharmSignal

Biotech News

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Day One Biopharmaceuticals (DAWN)Day One BiopharmaceuticalsConference / presentation

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15

Related news

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

GSKGSK plc2026-09-10 07:00 EST

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Day One Biopharmaceuticals

Pediatric and Rare Oncology Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types. OJEMDA OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an...

Recent company news

DAWNDay One Biopharmaceuticals2026-03-06 13:30 EST

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

DAWNDay One Biopharmaceuticals2026-02-24 21:00 EST

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

DAWNDay One Biopharmaceuticals2026-02-10 13:30 EST

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

DAWNDay One Biopharmaceuticals2026-01-11 22:00 EST

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

DAWNDay One Biopharmaceuticals2026-01-06 14:02 EST

Day One Completes Acquisition of Mersana Therapeutics

Stock data

Close
21.53 USD
Market cap
2.22B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States